A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients.
- EMBO Molecular Medicine
- Swedish Children's Cancer, Swedish Cancer Society, Swedish Medical Association, Clas Groschinsky Memorial Foundation, Mary Béve Foundation for Childhood Cancer Research, Harald och Greta Jeanssons Foundation, and others